CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) — the natural signal your hypothalamus uses to tell the pituitary gland to produce growth hormone. The key innovation of CJC-1295 is its extended half-life compared to natural GHRH, which degrades in minutes.
CJC-1295 comes in two forms: CJC-1295 with DAC (Drug Affinity Complex), which uses albumin binding to extend its half-life to approximately 6–8 days, and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF), which has a shorter half-life of about 30 minutes.
The peptide binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating a pulsatile release of growth hormone. This is a critical distinction from exogenous hGH injection — CJC-1295 works with your body's natural feedback loops rather than overriding them. The result is elevated growth hormone and IGF-1 levels within physiological ranges.
CJC-1295 is most commonly paired with Ipamorelin, a growth hormone secretagogue that acts on ghrelin receptors. Together, they amplify GH release synergistically without significant effects on cortisol or prolactin.
CJC-1295 has been studied in both animal models and human clinical trials, primarily for growth hormone deficiency and body composition.
GH & IGF-1 Elevation: A pivotal human study demonstrated that a single injection of CJC-1295 with DAC increased mean GH levels 2-10 fold and IGF-1 levels by 1.5-3 fold for 6+ days. These elevations remained within physiological ranges.
Body Composition: Clinical data shows improvements in lean body mass and reductions in body fat with sustained CJC-1295 use, consistent with the known effects of optimized growth hormone levels.
Sleep Quality: Growth hormone is primarily released during deep (Stage 3/4 NREM) sleep. By amplifying natural GH pulsatility, CJC-1295 users consistently report deeper, more restorative sleep — an effect supported by the known relationship between GHRH signaling and sleep architecture.
Recovery & Healing: Optimized GH/IGF-1 levels support tissue repair, collagen synthesis, and immune function. Athletes and active individuals report faster recovery from training when GH levels are optimized.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
CJC-1295 is administered via subcutaneous injection. The two forms have different dosing approaches.
CJC-1295 without DAC (Mod GRF 1-29) + Ipamorelin: 100 mcg of each, injected subcutaneously 2–3 times daily (upon waking, post-workout, and before bed). The pre-bed dose is considered most important for enhancing natural nighttime GH release. This is the most common pairing.
CJC-1295 with DAC: 2 mg subcutaneously, once or twice per week. The extended half-life allows less frequent dosing but produces a more continuous (less pulsatile) GH elevation.
Timing: Inject on an empty stomach or at least 30 minutes before eating. Fats and carbohydrates can blunt GH release via insulin and somatostatin.
Cycle Length: 8–12 weeks on, 4 weeks off. Some providers run longer cycles with periodic IGF-1 lab monitoring to ensure levels remain within range.
CJC-1295 is generally well-tolerated when dosed within standard ranges. Common effects include water retention (especially in the first 1–2 weeks), mild tingling or numbness in extremities, increased hunger (from GH-related effects), vivid dreams (from enhanced deep sleep), and occasional injection site reactions.
The most important safety consideration is monitoring IGF-1 levels via lab work. Chronically elevated IGF-1 has been associated with increased cancer risk in epidemiological studies. Providers typically recommend baseline and periodic IGF-1 testing to ensure levels remain within the physiological range.
Verified suppliers with third-party testing and COA documentation. Use code POWER where applicable.
CJC-1295 with DAC has an extended half-life of 6–8 days due to albumin binding, requiring only weekly injections but producing more continuous GH elevation. CJC-1295 without DAC (Mod GRF 1-29) has a 30-minute half-life, requiring multiple daily injections but producing a more natural pulsatile GH release pattern. Most providers prefer the no-DAC version for its physiological pulsatility.
CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) work through different receptors that synergize to amplify GH release. Together, they produce significantly greater GH output than either alone. Ipamorelin was chosen over other GH secretagogues because it doesn't significantly raise cortisol or prolactin levels.
No. CJC-1295 + Ipamorelin stimulates your pituitary to produce and release its own GH in a natural pulsatile pattern. Exogenous hGH injections bypass the pituitary entirely, which can cause feedback suppression of natural GH production. The peptide approach maintains your body's natural regulatory mechanisms.
Yes — this is one of the most consistently reported benefits. Growth hormone is primarily released during deep NREM sleep. By amplifying GHRH signaling, CJC-1295 enhances the depth and quality of slow-wave sleep. Many users report it as the most noticeable immediate benefit.
Take our 2-minute quiz to get a personalized peptide recommendation based on your goals, experience level, and health priorities.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. Peptide protocols described on this page reflect reported clinical practices and published research — not recommendations. Individual results may vary. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.